What is Puma Biotechnology Inc's earnings per share (EPS)?

Puma Biotechnology Inc (PBYI) reported diluted earnings per share of $0.61 for fiscal year 2025. This represents a -1.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Puma Biotechnology Inc (PBYI) Financials

PBYI

Trailing 12 months to June 30, 2026

Revenue $231.2M -2.9% YoY

Net Income $26.7M -44.9% YoY

EPS (Diluted) $0.52 -47.5% YoY

Free Cash Flow $41.1M -7.1% YoY

Market Cap $473.4M as of Sep 11, 2026

Price / Sales 2.0x on $231.2M revenue, trailing 12 months to June 30, 2026

Price / Earnings 17.7x on $26.7M net income, trailing 12 months to June 30, 2026

Price / Book 3.4x on $138.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 11, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PBYI SEC filings page.

Puma Biotechnology Inc (PBYI) reported $231.2M in revenue over the twelve months to Jun 30, 2026, down 2.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI PBYI FY2025 2026-08-29

Nearly unchanged sales now support expanding operating margins, cash generation, and a debt-free balance sheet through internal earnings.

Across the reported period, revenue remained near $228M-$230M, so scale—not demand growth explains the central operating change. Operating margin rose from 10.4% to 16.3%, indicating improved cost absorption or a favorable mix rather than a larger sales base.

The latest year's operating cash flow was $41.8M versus $31.1M of net income, showing that reported earnings converted into cash with help from non-cash or working-capital movements. Free cash flow reached $41.7M against only $71K of capital expenditures, so the cash profile is not being driven by heavy fixed-asset reinvestment.

Long-term debt fell from $65.7M to $0 over the reported period, making the financing structure less dependent on creditors. Current ratio increased from 1.6x to 2.0x, adding short-term flexibility alongside that structural deleveraging.

Financial Health Signals

Financial Health Score 69/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Puma Biotechnology Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Puma Biotechnology Inc has an operating margin of 16.3%, meaning the company retains $16 of operating profit per $100 of revenue. This strong profitability earns a score of 71/100, reflecting efficient cost management and pricing power. This is up from 13.4% the prior year.

Growth

Puma Biotechnology Inc's revenue declined 0.9% year-over-year, from $230.5M to $228.4M. This contraction results in a growth score of 26/100.

Leverage

Puma Biotechnology Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Puma Biotechnology Inc's current ratio of 2.00 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Puma Biotechnology Inc converts 18.3% of revenue into free cash flow ($41.7M). This strong cash generation earns a score of 81/100.

Returns

Puma Biotechnology Inc earns a strong 23.9% return on equity (ROE), meaning it generates $24 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 82/100. This is down from 32.9% the prior year.

Altman Z-Score Distress

-2.93

Puma Biotechnology Inc scores -2.93, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($473.4M) relative to total liabilities ($86.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Puma Biotechnology Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.34x

For every $1 of reported earnings, Puma Biotechnology Inc generates $1.34 in operating cash flow ($41.8M OCF vs $31.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

5.63x

Puma Biotechnology Inc earns $5.63 in operating income for every $1 of interest expense ($37.3M vs $6.6M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$56.5M

YoY+7.8%

QoQ+26.1%

5Y CAGR+1.1%

Puma Biotechnology Inc generated $56.5M in revenue in Q2 2026. This represents an increase of 7.8% from the same quarter a year earlier. Against the prior quarter it is up 26.1%.

EBITDA

$10.1M

YoY+10.6%

QoQ+912.0%

Puma Biotechnology Inc's EBITDA was $10.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 10.6% from the same quarter a year earlier. Against the prior quarter it is up 912.0%.

Net Income

$8.2M

YoY+39.9%

QoQ+318.2%

Puma Biotechnology Inc reported $8.2M in net income in Q2 2026. This represents an increase of 39.9% from the same quarter a year earlier. Against the prior quarter it is up 318.2%.

EPS (Diluted)

$0.16

YoY+33.3%

QoQ+328.6%

Puma Biotechnology Inc earned $0.16 per diluted share (EPS) in Q2 2026. This represents an increase of 33.3% from the same quarter a year earlier. Against the prior quarter it is up 328.6%.

Cash & Balance Sheet

Free Cash Flow

$1.6M

YoY-88.5%

QoQ-89.5%

Puma Biotechnology Inc generated $1.6M in free cash flow in Q2 2026, representing cash available after capex. This represents a decrease of 88.5% from the same quarter a year earlier. Against the prior quarter it is down 89.5%.

Cash & Debt

$36.5M

YoY-33.2%

QoQ+1.0%

5Y CAGR-16.5%

10Y CAGR-4.5%

Puma Biotechnology Inc held $36.5M in cash against $0 in long-term debt as of Q2 2026, with $49.8M of liabilities due within a year.

Shares Outstanding

52M

YoY+2.5%

QoQ+1.4%

5Y CAGR+4.8%

10Y CAGR+4.7%

Puma Biotechnology Inc had 52M shares outstanding in Q2 2026. This represents an increase of 2.5% from the same quarter a year earlier. Against the prior quarter it is up 1.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

77.9%

YoY+1.4pp

QoQ+1.2pp

5Y CAGR+0.3pp

Puma Biotechnology Inc's gross margin was 77.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 1.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.

Operating Margin

13.4%

YoY+0.8pp

QoQ+22.0pp

5Y CAGR+44.6pp

Puma Biotechnology Inc's operating margin was 13.4% in Q2 2026, reflecting core business profitability. This is up 0.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 22.0 percentage points.

Net Margin

14.5%

YoY+3.3pp

QoQ+22.9pp

5Y CAGR+24.1pp

Puma Biotechnology Inc's net profit margin was 14.5% in Q2 2026, showing the share of revenue converted to profit. This is up 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 22.9 percentage points.

Return on Equity

5.9%

YoY+0.3pp

QoQ+8.8pp

Puma Biotechnology Inc's ROE was 5.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.8 percentage points.

Capital Allocation

R&D Spending

$18.9M

YoY+22.3%

QoQ-4.5%

5Y CAGR+0.3%

Puma Biotechnology Inc invested $18.9M in research and development in Q2 2026. This represents an increase of 22.3% from the same quarter a year earlier. Against the prior quarter it is down 4.5%.

Capital Expenditures

YoY-100.0%

Puma Biotechnology Inc reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.

Share Buybacks

Not reported for Q2 2026.

PBYI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PBYI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$231.2M	$228.4M-0.9%	$230.5M-2.2%	$235.6M+3.3%	$228.0M-9.9%	$253.2M+12.5%	$225.1M-17.3%	$272.3M+8.5%	$251.0M+806.6%	$27.7M	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	$58.2M	$58.2M-9.7%	$64.4M+2.7%	$62.7M+13.8%	$55.1M-13.5%	$63.7M+61.8%	$39.4M+7.0%	$36.8M+6.3%	$34.6M+521.3%	$5.6M	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$173.0M	$170.2M+2.5%	$166.1M-4.0%	$173.0M0.0%	$172.9M-8.7%	$189.5M+2.0%	$185.7M-21.1%	$235.4M+8.8%	$216.4M+878.5%	$22.1M	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$71.4M	$62.1M+13.0%	$54.9M+9.0%	$50.4M-3.6%	$52.2M-27.3%	$71.9M-26.4%	$97.7M-26.5%	$132.9M-19.4%	$164.9M-20.7%	$207.8M-6.7%	$222.8M+6.9%	$208.5M+69.6%	$122.9M+172.9%	$45.0M-9.2%	$49.6M+5909.2%	$826K
SG&A Expenses	$71.2M	$70.8M-11.6%	$80.2M-10.9%	$89.9M-0.1%	$90.0M-22.6%	$116.3M-1.9%	$118.5M-16.3%	$141.6M-3.1%	$146.2M+37.0%	$106.7M+98.3%	$53.8M+69.1%	$31.8M+64.3%	$19.4M+97.8%	$9.8M-60.6%	$24.8M+165.9%	$9.3M
Operating Income	$30.4M	$37.3M+20.5%	$31.0M-5.1%	$32.6M+37.6%	$23.7M+1738.8%	$1.3M+104.2%	-$30.4M+22.1%	-$39.0M+58.8%	-$94.7M+67.6%	-$292.4M-5.7%	-$276.6M-15.1%	-$240.3M-68.9%	-$142.3M-159.5%	-$54.8M+26.3%	-$74.5M-633.0%	-$10.2M
EBITDA	N/A	$48.2M+13.5%	$42.5M-3.8%	$44.2M+31.6%	$33.6M+166.5%	$12.6M+161.8%	-$20.4M+34.2%	-$31.0M+64.5%	-$87.3M+69.9%	-$289.6M-5.1%	-$275.4M-15.0%	-$239.5M-69.1%	-$141.6M-160.3%	-$54.4M+26.7%	-$74.2M-631.2%	-$10.1M
Interest Expense	$3.5M	$6.6M-46.8%	$12.5M-6.6%	$13.3M+15.0%	$11.6M-9.5%	$12.8M-8.8%	$14.0M-6.5%	$15.0M+36.7%	$11.0M+1425.7%	$720K	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$4.7M+175.6%	-$6.2M-670.5%	$1.1M+138.0%	$455K+40.4%	$324K+56.5%	$207K+290.6%	$53K+211.8%	$17K	$0	$0	$0	$0	$0	$0	N/A
Net Income	$26.7M	$31.1M+2.8%	$30.3M+40.2%	$21.6M+1079450.0%	$2K-100.0%	$29.1M+148.5%	-$60.0M+20.6%	-$75.6M+33.4%	-$113.6M+61.1%	-$292.0M-5.8%	-$276.0M-15.3%	-$239.3M-68.6%	-$142.0M-159.7%	-$54.7M+26.5%	-$74.4M-626.6%	-$10.2M
EPS (Basic)	N/A	$0.620.0%	$0.62+34.8%	$0.46	$0.00+100.0%	-$0.72+52.6%	-$1.52+100.0%	-$75595.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	$0.52	$0.61-1.6%	$0.62+37.8%	$0.45	$0.00+100.0%	-$0.72+52.6%	-$1.52	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	51M+3.2%	49M+3.3%	48M+5.8%	45M+10.6%	41M+2.7%	40M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$56.5M+7.8%	$44.8M-2.6%	$75.5M+27.7%	$54.5M-32.4%	$52.4M+11.4%	$46.0M+5.1%	$59.1M-18.2%	$80.5M+43.5%
Cost of Revenue	$12.5M+1.4%	$10.4M-1.3%	$23.1M+66.1%	$12.2M-58.2%	$12.3M+15.4%	$10.6M-1.6%	$13.9M-42.8%	$29.1M+119.0%
Gross Profit	$44.0M+9.7%	$34.4M-3.0%	$52.3M+15.9%	$42.3M-17.8%	$40.1M+10.2%	$35.5M+7.3%	$45.2M-5.6%	$51.4M+20.1%
R&D Expenses	$18.9M+22.3%	$19.8M+42.8%	$16.8M+11.0%	$15.9M+26.8%	$15.5M+13.4%	$13.9M+2.0%	$15.2M+17.8%	$12.5M+9.6%
SG&A Expenses	$17.5M-2.8%	$18.4M+4.7%	$18.4M+10.6%	$16.8M0.0%	$18.0M-27.7%	$17.6M-19.1%	$16.6M-17.6%	$16.8M-26.2%
Operating Income	$7.6M+14.3%	-$3.8M-196.1%	$17.1M+28.0%	$9.6M-56.6%	$6.6M+404.5%	$4.0M+273.3%	$13.4M-9.7%	$22.1M+157.2%
EBITDA	$10.1M+10.6%	-$1.2M-118.3%	$20.2M+19.2%	$12.1M-50.9%	$9.1M+2746.1%	$6.8M+1033.8%	$17.0M-7.8%	$24.6M+121.7%
Interest Expense	$180K-90.2%	$731K-66.4%	$1.1M-57.3%	$1.5M-52.0%	$1.8M-45.5%	$2.2M-35.2%	$2.6M-21.9%	$3.1M-7.2%
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	-$7.1M-1418.5%	$291K+36.6%
Net Income	$8.2M+39.9%	-$3.8M-226.2%	$13.4M-30.4%	$8.8M-56.5%	$5.9M+229.3%	$3.0M+161.8%	$19.3M+57.4%	$20.3M+250.5%
EPS (Basic)	$0.16+33.3%	-$0.07-216.7%	$0.27-30.8%	$0.18-56.1%	$0.12+233.3%	$0.06+160.0%	$0.39+50.0%	$0.41+241.7%
EPS (Diluted)	$0.16+33.3%	-$0.07-216.7%	$0.26-35.0%	$0.17-58.5%	$0.12+233.3%	$0.06+160.0%	$0.40+60.0%	$0.41+241.7%
Diluted Shares (Avg)	53M+4.9%	51M+1.9%	N/A	51M+3.6%	50M+3.8%	50M+3.6%	N/A	49M+2.8%

PBYI Balance Sheet

PBYI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$216.3M+1.4%	$213.3M-7.5%	$230.5M+3.8%	$222.1M-2.0%	$226.6M-7.2%	$244.2M+4.0%	$234.9M-9.3%	$259.1M+56.5%	$165.5M-34.5%	$252.8M+5.4%	$239.8M+47.4%	$162.8M+55.9%	$104.4M-31.2%	$151.7M+173.8%	$55.4M
Current Assets	$162.7M+10.2%	$147.7M-5.5%	$156.2M+16.3%	$134.3M-4.1%	$140.0M-4.2%	$146.1M-12.1%	$166.3M-18.1%	$203.0M+90.8%	$106.4M-55.0%	$236.5M+5.8%	$223.5M+49.7%	$149.4M+55.0%	$96.4M-35.3%	$149.0M+177.6%	$53.7M
Cash & Equivalents	$29.6M-57.2%	$69.2M-18.2%	$84.6M+11.0%	$76.2M+20.7%	$63.1M-26.0%	$85.3M+42.1%	$60.0M-44.6%	$108.4M+32.7%	$81.7M-58.0%	$194.5M+516.1%	$31.6M-18.1%	$38.5M-10.5%	$43.0M-68.7%	$137.4M+157.4%	$53.4M
Short-Term Investments	$67.9M+113.9%	$31.7M+179.6%	$11.4M+133.0%	$4.9M-74.3%	$19.0M+134.4%	$8.1M-84.3%	$51.6M-9.5%	$57.0M	$0-100.0%	$35.0M-81.0%	$184.3M+79.3%	$102.8M+151.3%	$40.9M	$0	$0
Inventory	$5.5M-36.8%	$8.7M+23.2%	$7.1M+56.4%	$4.5M-36.3%	$7.1M+105.8%	$3.5M+9.0%	$3.2M+20.8%	$2.6M+29.4%	$2.0M	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$53.7M+67.6%	$32.0M-33.1%	$47.8M+18.6%	$40.4M+24.1%	$32.5M+27.3%	$25.5M-11.6%	$28.9M+39.1%	$20.8M+114.8%	$9.7M	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$86.0M-29.1%	$121.2M-31.6%	$177.1M-11.7%	$200.5M-12.5%	$229.0M-8.5%	$250.2M+15.1%	$217.4M-3.3%	$224.8M+100.3%	$112.2M+161.2%	$43.0M+27.0%	$33.8M-26.0%	$45.7M+124.2%	$20.4M-10.5%	$22.8M+2121.2%	$1.0M
Current Liabilities	$81.3M-15.5%	$96.1M-3.3%	$99.4M+28.3%	$77.5M-29.3%	$109.6M-4.1%	$114.3M+25.8%	$90.8M+35.3%	$67.1M+15.0%	$58.3M+55.7%	$37.5M+15.5%	$32.4M-27.0%	$44.4M+130.6%	$19.3M-11.2%	$21.7M+3596.9%	$587K
Non-Current Liabilities	$4.7M-81.2%	$25.1M-67.7%	$77.7M-36.8%	$123.0M+2.9%	$119.4M-12.1%	$135.9M+7.4%	$126.6M-19.7%	$157.7M+192.7%	$53.9M+878.8%	$5.5M+295.2%	$1.4M+9.8%	$1.3M+13.7%	$1.1M+2.5%	$1.1M+148.1%	$439K
Long-Term Debt	$0-100.0%	$21.7M-66.9%	$65.7M-33.2%	$98.3M+1.3%	$97.1M+15.6%	$84.0M-11.5%	$95.0M-37.5%	$151.9M+213.3%	$48.5M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$130.3M+41.5%	$92.1M+72.4%	$53.4M+147.3%	$21.6M+983.4%	-$2.4M+58.9%	-$6.0M-134.1%	$17.5M-49.1%	$34.3M-35.6%	$53.3M-74.6%	$209.8M+1.9%	$206.0M+76.0%	$117.0M+39.4%	$84.0M-34.8%	$128.9M+137.1%	$54.4M
Retained Earnings	-$1.3B+2.4%	-$1.3B+2.3%	-$1.3B+1.6%	-$1.4B0.0%	-$1.4B-2.2%	-$1.3B-4.7%	-$1.3B-6.3%	-$1.2B-10.4%	-$1.1B-36.7%	-$796.5M-53.0%	-$520.5M-85.1%	-$281.2M-101.9%	-$139.3M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$192.7M-1.1%	$192.7M-1.8%	$216.3M+1.4%	$202.9M-8.1%	$194.9M-4.9%	$196.2M-8.4%	$213.3M-7.5%	$220.7M+8.4%
Current Assets	$145.1M+6.2%	$142.3M+7.4%	$162.7M+10.2%	$143.6M-8.4%	$136.6M-0.8%	$132.5M-7.4%	$147.7M-5.5%	$156.8M+25.1%
Cash & Equivalents	$36.5M-33.2%	$36.2M-42.6%	$29.6M-57.2%	$53.5M-20.4%	$54.7M-18.6%	$63.0M-17.9%	$69.2M-18.2%	$67.3M-17.8%
Short-Term Investments	$57.4M+38.7%	$65.4M+116.8%	$67.9M+113.9%	$40.9M+38.7%	$41.4M+39.3%	$30.1M-0.9%	$31.7M+179.6%	$29.5M+812.4%
Inventory	$13.3M+55.1%	$8.7M-0.7%	$5.5M-36.8%	$9.5M+254.5%	$8.6M-5.1%	$8.8M+23.3%	$8.7M+23.2%	$2.7M-52.9%
Accounts Receivable	$34.1M+31.5%	$26.3M+4.6%	$53.7M+67.6%	$33.6M-38.6%	$25.9M-7.8%	$25.2M+2.4%	$32.0M-33.1%	$54.6M+88.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$54.2M-39.9%	$64.3M-35.1%	$86.0M-29.1%	$87.6M-41.5%	$90.2M-42.4%	$99.1M-39.3%	$121.2M-31.6%	$149.6M-9.2%
Current Liabilities	$49.8M-37.0%	$59.7M-31.1%	$81.3M-15.5%	$82.7M-25.1%	$79.1M-24.2%	$86.7M-11.7%	$96.1M-3.3%	$110.4M+63.9%
Non-Current Liabilities	$4.4M-60.7%	$4.5M-63.4%	$4.7M-81.2%	$4.9M-87.6%	$11.1M-78.7%	$12.4M-80.9%	$25.1M-67.7%	$39.2M-59.8%
Long-Term Debt	$0-100.0%	$0-100.0%	$0-100.0%	$0-100.0%	$10.9M-75.1%	$10.6M-80.5%	$21.7M-66.9%	$32.7M-57.3%
Total Equity	$138.5M+32.3%	$128.4M+32.2%	$130.3M+41.5%	$115.3M+62.1%	$104.7M+115.9%	$97.1M+90.5%	$92.1M+72.4%	$71.1M+83.5%
Retained Earnings	-$1.3B+2.0%	-$1.3B+1.9%	-$1.3B+2.4%	-$1.3B+2.8%	-$1.3B+3.6%	-$1.3B+2.8%	-$1.3B+2.3%	-$1.3B+1.7%

Not reported in any period shown, so not listed: Goodwill.

PBYI Cash Flow Statement

PBYI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$41.1M	$41.8M+7.4%	$38.9M+44.1%	$27.0M+270.7%	-$15.8M-176.6%	$20.6M+2571.4%	$773K-96.5%	$22.4M+192.8%	-$24.1M+86.0%	-$172.5M-21.7%	-$141.7M+8.3%	-$154.5M-100.1%	-$77.2M-40.2%	-$55.0M-25.1%	-$44.0M-2312.9%	-$1.8M
Depreciation & Amortization	N/A	$10.9M-5.1%	$11.5M0.0%	$11.5M+17.1%	$9.8M-13.0%	$11.3M+12.7%	$10.0M+24.2%	$8.1M+9.4%	$7.4M+162.7%	$2.8M+144.6%	$1.1M+48.1%	$776K+23.8%	$627K+48.2%	$423K+59.6%	$265K+2309.1%	$11K
Stock-Based Compensation	N/A	$6.9M-15.8%	$8.2M-19.5%	$10.2M-13.4%	$11.8M-63.8%	$32.6M-10.8%	$36.6M-36.2%	$57.3M-34.1%	$86.9M-20.0%	$108.7M-7.3%	$117.3M+23.5%	$94.9M+142.5%	$39.2M+420.7%	$7.5M-61.7%	$19.6M+29198.5%	$67K
Capital Expenditures	-$10K	$71K+26.8%	$56K-60.0%	$140K	$0	$0-100.0%	$46K-85.0%	$306K-30.3%	$439K+1.9%	$431K-89.9%	$4.3M+327.8%	$1.0M-8.9%	$1.1M+76.3%	$624K	N/A	$253K
Free Cash Flow	$41.1M	$41.7M+7.4%	$38.9M+44.6%	$26.9M+269.8%	-$15.8M-176.6%	$20.6M+2740.4%	$727K-96.7%	$22.1M+189.9%	-$24.5M+85.8%	-$172.9M-18.4%	-$146.0M+6.1%	-$155.5M-98.5%	-$78.3M-40.7%	-$55.7M	N/A	-$2.1M
Investing Cash Flow	-$16.0M	-$36.2M-77.1%	-$20.4M-6.9%	-$19.1M-369.2%	$7.1M+165.3%	-$10.9M-132.6%	$33.4M+547.0%	$5.2M+109.0%	-$57.6M-273.3%	-$15.4M-110.9%	$142.2M	N/A	N/A	-$41.5M-3301.4%	-$1.2M+30.1%	-$1.7M
Financing Cash Flow	-$45.3M	-$45.2M-33.5%	-$33.8M	$0-100.0%	$12.2M+138.3%	-$31.9M-221.5%	-$9.9M+85.2%	-$67.1M-161.8%	$108.5M+44.4%	$75.1M-53.8%	$162.4M	N/A	N/A	$2.2M-98.3%	$129.3M+127.0%	$57.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$1.6M-88.5%	$15.4M+326.8%	$14.4M-7.6%	$9.7M-12.2%	$14.1M+1271.2%	$3.6M-67.9%	$15.6M+49.3%	$11.0M+4.0%
Depreciation & Amortization	$2.5M+0.6%	$2.6M-7.6%	$2.7M-6.5%	$2.5M0.0%	$2.5M0.0%	$2.8M-3.5%	$2.8M-1.7%	$2.5M0.0%
Stock-Based Compensation	$2.0M+20.0%	$1.9M-6.4%	N/A	$1.7M-18.5%	$1.6M-21.0%	$2.0M-14.8%	N/A	$2.1M-19.3%
Capital Expenditures	$0-100.0%	$0-100.0%	-$36K+125.0%	$26K+30.0%	$20K0.0%	$61K	$16K-64.4%	$20K-25.9%
Free Cash Flow	$1.6M-88.5%	$15.4M+334.1%	$14.4M-7.7%	$9.7M-12.3%	$14.1M+1296.4%	$3.6M-68.4%	$15.6M+49.8%	$11.0M+4.1%
Investing Cash Flow	$8.0M+170.9%	$2.5M+61.6%	-$27.0M-1062.8%	$506K+95.4%	-$11.2M-1700.0%	$1.5M+108.0%	-$2.3M+71.6%	$259K-97.7%
Financing Cash Flow	-$11.3M-1.3%	-$11.3M0.0%	-$11.3M0.0%	-$11.3M-1.3%	-$11.2M+1.1%	-$11.3M	-$11.3M	-$11.2M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

PBYI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

PBYI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	74.5%+2.5pp	72.1%-1.3pp	73.4%-2.4pp	75.8%+1.0pp	74.8%-7.7pp	82.5%-4.0pp	86.5%+0.3pp	86.2%+6.3pp	79.9%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	16.3%+2.9pp	13.4%-0.4pp	13.9%+3.5pp	10.4%+9.9pp	0.5%+14.0pp	-13.5%+0.8pp	-14.3%+23.4pp	-37.7%	-1056.1%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	13.6%+0.5pp	13.1%+4.0pp	9.2%+9.2pp	0.0%-11.5pp	11.5%+38.2pp	-26.7%+1.1pp	-27.8%+17.5pp	-45.3%	-1054.6%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	23.9%-9.0pp	32.9%-7.5pp	40.4%+40.4pp	0.0%	N/A	N/A	-432.9%-101.8pp	-331.1%+216.7pp	-547.7%-416.2pp	-131.5%-15.4pp	-116.1%+5.1pp	-121.3%-56.2pp	-65.1%-7.4pp	-57.7%-38.9pp	-18.8%
Return on Assets	14.4%+0.2pp	14.2%+4.8pp	9.4%+9.4pp	0.0%-12.8pp	12.8%+37.4pp	-24.6%+7.6pp	-32.2%+11.7pp	-43.8%+132.5pp	-176.4%-67.2pp	-109.2%-9.4pp	-99.8%-12.6pp	-87.2%-34.8pp	-52.4%-3.4pp	-49.0%-30.5pp	-18.5%
Current Ratio	2.00+0.5x	1.540.0x	1.57-0.2x	1.73+0.5x	1.280.0x	1.28-0.6x	1.83-1.2x	3.02+1.2x	1.82-4.5x	6.31-0.6x	6.89+3.5x	3.36-1.6x	5.00-1.9x	6.86-84.6x	91.42
Debt-to-Equity	0.00-0.2x	0.24-1.0x	1.23-3.3x	4.55	N/A	N/A	5.44+1.0x	4.43+3.5x	0.91+0.7x	0.200.0x	0.16-0.2x	0.39+0.1x	0.24+0.1x	0.18+0.2x	0.02
Asset Turnover	1.060.0x	1.08+0.1x	1.020.0x	1.03-0.1x	1.12+0.2x	0.92-0.2x	1.16+0.2x	0.97+0.8x	0.17	N/A	N/A	N/A	N/A	N/A	N/A
FCF Margin	18.3%+1.4pp	16.9%+5.5pp	11.4%+18.3pp	-6.9%-15.1pp	8.2%+7.8pp	0.3%-7.8pp	8.1%+17.9pp	-9.8%	-624.5%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	77.9%+1.4pp	76.7%-0.3pp	69.3%-7.1pp	77.6%+13.8pp	76.5%-0.8pp	77.1%+1.6pp	76.4%+10.1pp	63.9%-12.5pp
Operating Margin	13.4%+0.8pp	-8.5%-17.2pp	22.7%+0.1pp	17.6%-9.8pp	12.7%+17.3pp	8.7%+13.9pp	22.6%+2.1pp	27.4%+12.1pp
Net Margin	14.5%+3.3pp	-8.4%-14.8pp	17.8%-14.9pp	16.2%-9.0pp	11.2%+20.8pp	6.5%+17.5pp	32.7%+15.7pp	25.2%+14.9pp
Return on Equity	5.9%+0.3pp	-2.9%-6.0pp	10.3%-10.7pp	7.7%-20.9pp	5.6%+14.9pp	3.1%+12.5pp	21.0%-2.0pp	28.6%+13.6pp
Return on Assets	4.3%+1.3pp	-1.9%-3.5pp	6.2%-2.8pp	4.4%-4.8pp	3.0%+5.2pp	1.5%+3.8pp	9.0%+3.7pp	9.2%+6.3pp
Current Ratio	2.91+1.2x	2.38+0.9x	2.00+0.5x	1.74+0.3x	1.73+0.4x	1.53+0.1x	1.540.0x	1.42-0.4x
Debt-to-Equity	0.00-0.1x	0.00-0.1x	0.00-0.2x	0.00-0.5x	0.10-0.8x	0.11-1.0x	0.24-1.0x	0.46-1.5x
Asset Turnover	0.290.0x	0.230.0x	0.35+0.1x	0.27-0.1x	0.270.0x	0.230.0x	0.280.0x	0.36+0.1x
FCF Margin	2.9%-23.9pp	34.4%+26.7pp	19.1%-7.3pp	17.7%+4.1pp	26.8%+24.7pp	7.7%-18.0pp	26.4%+12.0pp	13.7%-5.2pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Puma Biotechnology Inc PBYI	FY2025	$228.4M	$31.1M	13.6%	$473.4M	69/100
Silence Therapeutics Plc SLN	FY2025	$559K	-$88.6M	N/A	$827.3M	—
Tonix Pharmaceut TNXP	FY2025	$13.1M	-$124.0M	N/A	$210.6M	69/100

Where Puma Biotechnology Inc Ranks

Frequently Asked Questions

What is Puma Biotechnology Inc's annual revenue?

Puma Biotechnology Inc (PBYI) reported $228.4M in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Puma Biotechnology Inc's revenue growing?

Puma Biotechnology Inc (PBYI) revenue declined by 0.9% year-over-year, from $230.5M to $228.4M in fiscal year 2025.

Is Puma Biotechnology Inc profitable?

Yes, Puma Biotechnology Inc (PBYI) reported a net income of $31.1M in fiscal year 2025, with a net profit margin of 13.6%.

What is Puma Biotechnology Inc's EBITDA?

Puma Biotechnology Inc (PBYI) had EBITDA of $48.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Puma Biotechnology Inc have?

As of fiscal year 2025, Puma Biotechnology Inc (PBYI) had $29.6M in cash and equivalents against $0 in long-term debt.

What is Puma Biotechnology Inc's gross margin?

Puma Biotechnology Inc (PBYI) had a gross margin of 74.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Puma Biotechnology Inc's operating margin?

Puma Biotechnology Inc (PBYI) had an operating margin of 16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Puma Biotechnology Inc's net profit margin?

Puma Biotechnology Inc (PBYI) had a net profit margin of 13.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Puma Biotechnology Inc's return on equity (ROE)?

Puma Biotechnology Inc (PBYI) has a return on equity of 23.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Puma Biotechnology Inc's free cash flow?

Puma Biotechnology Inc (PBYI) generated $41.7M in free cash flow during fiscal year 2025. This represents a 7.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Puma Biotechnology Inc's operating cash flow?

Puma Biotechnology Inc (PBYI) generated $41.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Puma Biotechnology Inc's total assets?

Puma Biotechnology Inc (PBYI) had $216.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Puma Biotechnology Inc's capital expenditures?

Puma Biotechnology Inc (PBYI) invested $71K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Puma Biotechnology Inc spend on research and development?

Puma Biotechnology Inc (PBYI) invested $62.1M in research and development during fiscal year 2025.

How many shares does Puma Biotechnology Inc have outstanding?

Puma Biotechnology Inc (PBYI) had 51M shares outstanding as of fiscal year 2025.

What is Puma Biotechnology Inc's current ratio?

Puma Biotechnology Inc (PBYI) had a current ratio of 2.00 as of fiscal year 2025, which is generally considered healthy.

What is Puma Biotechnology Inc's debt-to-equity ratio?

Puma Biotechnology Inc (PBYI) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Puma Biotechnology Inc's return on assets (ROA)?

Puma Biotechnology Inc (PBYI) had a return on assets of 14.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Puma Biotechnology Inc's P/E ratio?

Puma Biotechnology Inc (PBYI) trades at 17.7x earnings, its market capitalization divided by net income of $26.7M net income, trailing 12 months to June 30, 2026. The market capitalization is $473.4M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Puma Biotechnology Inc's price-to-sales ratio?

Puma Biotechnology Inc (PBYI) trades at 2.0x sales, its market capitalization divided by revenue of $231.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $473.4M as of Sep 11, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Puma Biotechnology Inc's Altman Z-Score?

Puma Biotechnology Inc (PBYI) has an Altman Z-Score of -2.93, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Puma Biotechnology Inc's Piotroski F-Score?

Puma Biotechnology Inc (PBYI) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Puma Biotechnology Inc's earnings high quality?

Puma Biotechnology Inc (PBYI) has an earnings quality ratio of 1.34x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Puma Biotechnology Inc cover its interest payments?

Puma Biotechnology Inc (PBYI) has an interest coverage ratio of 5.63x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Puma Biotechnology Inc?

Puma Biotechnology Inc (PBYI) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.